Gammon David C, Dutton Traci, Piperdi Bilal, Zybert Jason, Wolfe Steven H, Nguyen Erin, Sbat Dalia, Pillarisetty Venu G, Sullivan Mary, Whalen Giles F
Pharmacy Consultant II, Clinical Pharmacy Services, Commonwealth Medicine, University of Massachusetts Medical School, Worcester, MA 01545, USA.
Am J Health Syst Pharm. 2009 Jul 1;66(13):1186-90. doi: 10.2146/ajhp080019.
Cytoreductive surgery (CS) and intraperitoneal hyperthermic chemotherapy (IPHC) in the treatment of peritoneal carcinomatosis (PC) in 15 patients are described.
Fifteen patients with PC who were treated with CS and IPHC were retrospectively identified between January 2002 and December 2006. All patients underwent cytoreduction immediately followed by IPHC with mitomycin or cisplatin. The time between undergoing CS and IPHC and the date of the last follow-up appointment or the date of death was used to calculate survival data for each patient. Nine patients had complete cytoreduction, and all but one patient had evidence of invasive disease at the time of surgery. Eleven patients required concomitant bowel resection at the time of debulking. Thirteen patients required blood transfusions during the perioperative period. Nine patients were discharged home, and four were discharged to a rehabilitation facility. Two patients died during the perioperative hospital admission, both of whom had a preoperative Eastern Cooperative Oncology Group (ECOG) performance status score of 2. The median survival time was 8.4 months, similar to the findings of previously published studies. Further studies are needed to see if tumor type, ECOG performance status score, degree of cytoreduction, and the chemotherapy agent used in IPHC can be correlated to quality of life and survival in patients with heterogeneous primary sources of intraabdominal malignancies.
Combination treatment with CS followed by IPHC in 15 patients with heterogeneous primary sources of intraabdominal malignancies resulted in a median survival time of 8.4 months.
描述15例腹膜癌患者接受细胞减灭术（CS）和腹腔内热化疗（IPHC）的治疗情况。
回顾性分析2002年1月至2006年12月期间接受CS和IPHC治疗的15例腹膜癌患者。所有患者均先进行细胞减灭术，随后立即接受丝裂霉素或顺铂腹腔内热化疗。用接受CS和IPHC的时间与最后一次随访日期或死亡日期来计算每位患者的生存数据。9例患者实现了完全细胞减灭，除1例患者外，其余所有患者在手术时均有浸润性疾病证据。11例患者在减瘤手术时需要同时进行肠切除术。13例患者在围手术期需要输血。9例患者出院回家，4例患者出院后前往康复机构。2例患者在围手术期住院期间死亡，这2例患者术前东部肿瘤协作组（ECOG）体能状态评分为2分。中位生存时间为8.4个月，与先前发表的研究结果相似。需要进一步研究以确定肿瘤类型、ECOG体能状态评分、细胞减灭程度以及IPHC中使用的化疗药物是否与腹腔内恶性肿瘤原发灶各异的患者的生活质量和生存情况相关。
15例腹腔内恶性肿瘤原发灶各异患者接受CS联合IPHC治疗，中位生存时间为8.4个月。
